Korea Looks To Close Gap In AI Drug Development Capabilities
Syntekabio Offering Multiple Platforms
Syntekabio CSO HeaKyoung Cho talks to Scrip how the AI-driven drug development situation in Korea compares with global trends and what the domestic industry needs to do to survive rising competition at home and abroad.
